Emendo Biotherapeutics Leaders Share Expert Insights on Cutting-Edge Gene Editing Advancements at October Industry Conferences

Executive Team Charts Path to Future Approval as the World Awaits a Historic Breakthrough in Precision Medicine

New York – Emendo Biotherapeutics (EmendoBio), a nuclease discovery and gene editing therapeutics company, today announced its participation in three premier gene editing conferences, reinforcing its strong reputation as an industry thought leader in the field of precision medicine.

David Baram, EmendoBio’s President & CEO, will kick off the event-filled month by participating in an engaging panel on gene editing at Chardan's 7th Annual Genetic Medicines Conference. The session, held on October 3 in New York, will cover recent breakthroughs, future predictions, and more.

Shortly after, Chief Business Officer Rachel Diamant, will address attendees at the Meeting on the Mesa in San Diego, California. The conference runs from October 10^th-12^th, with Rachel’s presentation scheduled for October 11 at 3:45 p.m. (local time), where she will provide insights and updates from EmendoBio’s labs as the company nears the clinic with its lead indication, EMD-101, for severe congenital neutropenia (SCN).

EmendoBio’s VP of Pre-clinical Research, Ira Gotliv, will close out the month with a presentation at the European Society of Cell & Gene Medicine’s (ESGCT) 30^th Annual Congress. The conference will convene in Brussels (October 24-27) and include educational sessions, workshops, and in-depth sessions from top industry leaders. Ira’s presentation will explore EMD-301 – a potent “one and done” gene editing-based therapy for hypercholesterolemia-related disorders that regulates LDLR expression and boosts LDL-C uptake. Attend the session on October 27th at 11 a.m. (local time).

At the forefront of the next generation of gene editing, EmendoBio will continue to lead important discussions at high-profile industry events, helping to usher in a new era of optimism around the future of gene editing and precision medicine.

For more information on EmendoBio and its growing pipeline, visit: emendobio.com

About Emendo Biotherapeutics

EmendoBio is a next-generation CRISPR gene editing company leveraging a triple proprietary technology platform to enable high precision gene editing throughout the genome. EmendoBio’s novel nuclease discovery platform, OMNI, broadens the targetable range of the genome while its target-specific optimization platform enables highly precise editing, utilized by novel editing strategies while maintaining high efficiencies. The capabilities of the OMNI technology platform, along with deep expertise in genomic medicine, protein engineering, and therapeutic development, provide EmendoBio with a unique advantage when addressing indications within hematology, cardiovascular, ophthalmology, and other disease areas.